1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
Hepatocellular Carcinoma: Competitive Landscape to 2026

Hepatocellular Carcinoma: Competitive Landscape to 2026

  • November 2018
  • 50 pages
  • ID: 5663975

Summary

Table of Contents

Search Inside

Hepatocellular Carcinoma: Competitive Landscape to 2026

Summary
Hepatocellular Carcinoma (HCC) is the most common type of liver cancer.It is the sixth most common type of cancer, accounts for around 90% of primary liver cancers, and is third most common cause of cancer mortality.

Hepatocellular Carcinoma (HCC) is particularly aggressive and has a poor survival rate (five-year survival <5%) and therefore remains an important public health issue worldwide.

In Asia and Africa, factors for development include Hepatitis B and C infection, aflatoxin exposure (from crops), liver cirrhosis and hemochromatosis, while in developed countries, factors for development include diabetes, obesity and Non-Alcoholic Steatohepatitis (NASH). For unresectable Hepatocellular Carcinoma (HCC), the standard of care, Bayer’s Nexavar (sorafenib), prolongs survival by just three months, therefore more treatment options are needed.

Currently, the Hepatocellular Carcinoma (HCC) pipeline features 319 products across all stages of clinical development.TKIs and PD1/PDL1 inhibitors remain a key focus of development, and their investigation in combination with each other or with other drug classes is increasing.

The early-stage pipeline is dominated by small molecules, but also includes mAbs, vaccines, and gene therapies.

Eli Lilly’s Cyramza (ramucirumab), which has shown a modest but significant survival benefit in Phase III clinical trials, is set to be the first VEGF inhibitor approved for Hepatocellular Carcinoma (HCC) treatment. PD1/PDL1 inhibitors combined with TKIs, CTLA4 inhibitors, or VEGF inhibitors are set to launch across the 8MM (United States, China, Italy, France, Japan, Germany, Spain and United Kingdom) starting from 2021.

"Hepatocellular Carcinoma: Competitive Landscape to 2026", report provides an assessment of the pipeline, clinical, and commercial landscape of HCC. Overall, it is expected that new drug approvals will drive Hepatocellular Carcinoma (HCC) market growth over the next decade (2016-2026).

Scope
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trial Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HCC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Clinical Trials - Current Trends and Recent Advancement

Global Clinical Trials - Current Trends and Recent Advancement

  • $ 2995
  • January 2019

Global Clinical Trials - Current Trends and Recent AdvancementSummaryThere has been tremendous innovation over the past decade with the emergence of new drugs with increasing adoption of targeted therapies ...

Acute Asthma Global Clinical Trials Review, H2, 2018

Acute Asthma Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Acute Asthma Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Acute Asthma Global Clinical Trials Review, H2, 2018" provides an overview of Acute Asthma clinical trials ...

Acne And Related Disorders Global Clinical Trials Review, H2, 2018

Acne And Related Disorders Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018

Acne And Related Disorders Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Acne And Related Disorders Global Clinical Trials Review, H2, 2018" provides an overview ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on